Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 3
2001 3
2002 79
2003 128
2004 159
2005 234
2006 256
2007 343
2008 356
2009 431
2010 587
2011 638
2012 739
2013 860
2014 1011
2015 1002
2016 1041
2017 1088
2018 1249
2019 1484
2020 1751
2021 1948
2022 2268
2023 2143
2024 883

Text availability

Article attribute

Article type

Publication date

Search Results

18,453 results

Results by year

Filters applied: . Clear all
Page 1
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
Wagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, Farlow MR, Clifford DB, Supnet-Bell C, Santacruz AM, Aschenbrenner AJ, Hassenstab JJ, Benzinger TLS, Gordon BA, Coalier KA, Cruchaga C, Ibanez L, Perrin RJ, Xiong C, Li Y, Morris JC, Lah JJ, Berman SB, Roberson ED, van Dyck CH, Galasko D, Gauthier S, Hsiung GR, Brooks WS, Pariente J, Mummery CJ, Day GS, Ringman JM, Mendez PC, St George-Hyslop P, Fox NC, Suzuki K, Okhravi HR, Chhatwal J, Levin J, Jucker M, Sims JR, Holdridge KC, Proctor NK, Yaari R, Andersen SW, Mancini M, Llibre-Guerra J, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network–Trials Unit. Wagemann O, et al. Among authors: li y. JAMA Neurol. 2024 Apr 29. doi: 10.1001/jamaneurol.2024.0991. Online ahead of print. JAMA Neurol. 2024. PMID: 38683602
Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study.
Zhu Y, Huang C, Zheng L, Li Q, Ge J, Geng S, Zhai M, Chen X, Yuan H, Li Y, Jia W, Sun K, Li Y, Ye T, Zhao Z, Liu H, Liu Z, Jiang H. Zhu Y, et al. Among authors: li y. Stem Cell Res Ther. 2024 Apr 29;15(1):122. doi: 10.1186/s13287-024-03707-2. Stem Cell Res Ther. 2024. PMID: 38679727 Free PMC article. Clinical Trial.
18,453 results
You have reached the last available page of results. Please see the User Guide for more information.